Br J Ophthalmol 90:889-893 doi:10.1136/bjo.2005.089219
  • Clinical science
    • Extended reports

Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma

  1. A Mohan1,
  2. M Kandalam1,
  3. H L Ramkumar2,
  4. L Gopal3,
  5. S Krishnakumar4
  1. 1Department of Ocular Pathology, Vision Research Foundation, Chennai, Tamil Nadu, India
  2. 2Department of Biological Sciences, Northwestern University, Evanston, IL, USA
  3. 3Vitreoretina Services, Vision Research Foundation, Chennai, Tamil Nadu, India
  4. 4Department of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, Chennai, India
  1. Correspondence to: Dr Subramanian Krishnakumar Department of Ocular Pathology, Vision Research Foundation, Sankara Nethralaya, 18, College Road, Chennai – 600 006, Tamil Nadu, India; drkrishnakumar_2000{at}
  • Accepted 2 March 2006
  • Published Online First 23 March 2006


Backgound/aim: The authors studied the expression of cancer stem cell surface marker, ABCG2, and neural stem cell marker, MCM2, in retinoblastoma and correlated clinicopathologically.

Methods: Among 39 retinoblastomas, 18 tumours were not subjected to preoperative/postoperative chemotherapy, 15 tumours underwent postoperative chemotherapy, and six tumours had preoperative chemotherapy. There were 20 tumours with no invasion and 19 tumours with invasion of choroid/optic nerve. ABCG2 and MCM2 expression was studied by immunohistochemistry.

Results: ABCG2 was positive in six of six and MCM2 was positive in five of six tumours that had recurred in the orbit or metastasised. ABCG2 was positive in 15/19 tumours with invasion. MCM2 was positive in 16/19 tumours with invasion. Invasive tumours showed higher expression of ABCG2 (p<0.01) and MCM2 (p<0.01) proteins. There was no correlation with differentiation and laterality of the tumours. Non-neoplastic retina was positive for ABCG2 and MCM2.

Conclusion: ABCG2 and MCM2 were expressed more in invasive tumours. Further studies are needed to understand the significance of ABCG2 and MCM2 expression in retinoblastoma.


  • Sponsors: Indian Council of Medical Research, (BMS-80/7/2003-01300) and Vision Research Foundation, Chennai, India.

  • Commercial interest: none.

Register for free content

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article